<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ERTACZO- sertaconazole nitrate cream </strong><br>Valeant Pharmaceuticals North America LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use ERTACZO cream safely and effectively. See full prescribing information for ERTACZO cream.<br><br>ERTACZO<span class="Sup">®</span> (sertaconazole nitrate) cream, 2%, for topical use<br><br>Initial U.S. Approval: 2003</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">ERTACZO cream 2% is an azole antifungal indicated for the topical treatment of interdigital <span class="product-label-link" type="condition" conceptid="133141" conceptname="Tinea pedis">tinea pedis</span> in immunocompetent patients 12 years of age and older, caused by: <span class="Italics">Trichophyton rubrum, Trichophyton mentagrophytes,</span> and <span class="Italics">Epidermophyton floccosum</span>. (<a href="#S1">1</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">ERTACZO cream should be applied to the affected and immediate surrounding area(s) twice daily for 4 weeks. (<a href="#S2">2</a>) </p>
<p class="Highlighta">Not for ophthalmic, oral, or intravaginal use. (<a href="#S2">2</a>) </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Cream, 2%. (<a href="#S3">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">None. (<a href="#S4">4</a>) </p></div>
</div>
<div><div></div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions observed in clinical trials (incidence &gt;2%) were <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">contact dermatitis</span>, <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>, <span class="product-label-link" type="condition" conceptid="4010479" conceptname="Sensation of burning of skin">burning skin</span>, application site <span class="product-label-link" type="condition" conceptid="4115411" conceptname="Pain of skin">skin tenderness</span>. (<a href="#S6.1">6.1</a>) </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Valeant Pharmaceuticals North America LLC at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div></div>
<div></div>
</div>
<div>
<div><div></div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 1/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2DOSAGE AND ADMINISTRATION</a></h1>
<h1><a href="#section-3" class="toc">3DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1Local Adverse Reactions</a></h2>
<h1><a href="#section-6" class="toc">6ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">8USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-7.1" class="toc">8.1Pregnancy</a></h2>
<h2><a href="#section-7.2" class="toc">8.3Nursing Mothers</a></h2>
<h2><a href="#section-7.3" class="toc">8.4Pediatric Use</a></h2>
<h2><a href="#section-7.4" class="toc">8.5Geriatric Use</a></h2>
<h1><a href="#section-8" class="toc">11DESCRIPTION</a></h1>
<h1><a href="#section-9" class="toc">12CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-9.1" class="toc">12.1Mechanism of Action</a></h2>
<h2><a href="#section-9.2" class="toc">12.3Pharmacokinetics </a></h2>
<h2><a href="#section-9.3" class="toc">12.4Microbiology</a></h2>
<h1><a href="#section-10" class="toc">13NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-10.1" class="toc">13.1Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-11" class="toc">14CLINICAL STUDIES</a></h1>
<h1><a href="#section-12" class="toc">16HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-13" class="toc">17PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1INDICATIONS AND USAGE</h1>
<p class="First">ERTACZO<span class="Sup">®</span> (sertaconazole nitrate) cream, 2%, is indicated for the topical treatment of interdigital <span class="product-label-link" type="condition" conceptid="133141" conceptname="Tinea pedis">tinea pedis</span> in immunocompetent patients 12 years of age and older, caused by: <span class="Italics">Trichophyton rubrum</span>, <span class="Italics">Trichophyton mentagrophytes, </span>and <span class="Italics">Epidermophyton floccosum</span> [see <span class="Italics"><a href="#S14">Clinical Studies (14)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2DOSAGE AND ADMINISTRATION</h1>
<p class="First">In the treatment of interdigital <span class="product-label-link" type="condition" conceptid="133141" conceptname="Tinea pedis">tinea pedis</span>, ERTACZO cream, 2%, should be applied twice daily for 4 weeks. Sufficient amount of ERTACZO cream, 2%, should be applied to cover both the affected areas between the toes and the immediately surrounding healthy skin of patients with interdigital <span class="product-label-link" type="condition" conceptid="133141" conceptname="Tinea pedis">tinea pedis</span>.</p>
<p>Not for ophthalmic, oral, or intravaginal use.</p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Cream, 2%. Each gram of ERTACZO cream, 2%, contains 17.5 mg of sertaconazole (as sertaconazole nitrate, 20 mg) in a white cream base.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4CONTRAINDICATIONS</h1>
<p class="First">None.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1Local Adverse Reactions</h2>
<p class="First">If irritation develops, treatment should be discontinued and appropriate therapy instituted.</p>
<p>Physicians should exercise caution when prescribing ERTACZO cream, 2%, to patients known to be sensitive to imidazole antifungals, since cross-reactivity may occur.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug, and may not reflect the rates observed in practice.</p>
<p>In clinical trials, cutaneous adverse events occurred in 7 of 297 (2%) subjects (2 of them severe) receiving ERTACZO<span class="Sup">®</span> cream, 2%, and in 7 of 291 (2%) subjects (2 of them severe) receiving vehicle. These reported cutaneous adverse events included <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">contact dermatitis</span>, <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>, <span class="product-label-link" type="condition" conceptid="4010479" conceptname="Sensation of burning of skin">burning skin</span>, application site <span class="product-label-link" type="condition" conceptid="4115411" conceptname="Pain of skin">skin tenderness</span>.</p>
<p>In a dermal sensitization trial, 8 of 202 evaluable subjects tested with ERTACZO<span class="Sup">®</span> cream, 2%, and 4 of 202 evaluable subjects tested with vehicle, exhibited a slight erythematous reaction in the challenge phase. There was no evidence of cumulative irritation or contact sensitization in a repeated insult patch test involving 202 healthy volunteers.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during post-approval use of ERTACZO cream, 2%. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p>In post-marketing surveillance for ERTACZO cream, 2%, the following were reported:</p>
<p>Cutaneous adverse events: <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, vesiculation, <span class="product-label-link" type="condition" conceptid="135029" conceptname="Peeling of skin">desquamation</span>, and hyperpigmentation.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-7"></a><p></p>
<h1>8USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-7.1"></a><p></p>
<h2>8.1Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="ID_b82f2850-3622-4d4f-bc7f-5e03c36bd881"></a><a name="section-7.1.1"></a><p></p>
<p class="First">Pregnancy Category C.</p>
<p>There are no adequate and well-controlled studies conducted with ERTACZO cream in pregnant women. ERTACZO cream should be used during pregnancy only if  the potential benefit justifies the potential risk to the fetus.</p>
<p>Reproduction studies have not been performed with ERTACZO cream. Sertaconazole nitrate did not produce any evidence of maternal toxicity, embryotoxicity or <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> in rats and rabbits at an oral dose of 160 mg/kg/day (40 times (rats) and 80 times (rabbits) the maximum recommended human dose based on a body surface area comparison). A reduction in live birth indices and an increase in the number of still-born pups were seen at doses of 80 and 160 mg/kg/day sertaconazole nitrate in an oral peri- and post-natal development study in rats.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-7.2"></a><p></p>
<h2>8.3Nursing Mothers</h2>
<p class="First">It is not known if sertaconazole is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when prescribing ERTACZO cream, 2%, to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-7.3"></a><p></p>
<h2>8.4Pediatric Use</h2>
<p class="First">The efficacy and safety of ERTACZO cream, 2%, have not been established in pediatric patients below the age of 12 years.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-7.4"></a><p></p>
<h2>8.5Geriatric Use</h2>
<p class="First">Clinical trials of ERTACZO cream, 2%, did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-8"></a><p></p>
<h1>11DESCRIPTION</h1>
<p class="First">ERTACZO (sertaconazole nitrate) cream, 2%, is for topical application. It contains the azole antifungal, sertaconazole nitrate. Sertaconazole nitrate contains one asymmetric carbon atom and exists as a racemic mixture of equal amounts of R and S enantiomers.</p>
<p>Sertaconazole nitrate is designated chemically as (±)-1-[2,4-dichloro-β-[(7-chlorobenzo-[<span class="Italics">b</span>]thien-3-yl)methoxy]phenethyl]imidazole nitrate. It has a molecular weight of 500.8. The molecular formula is C<span class="Sub">20</span>H<span class="Sub">15</span>Cl<span class="Sub">3</span>N<span class="Sub">2</span>OS <span class="Bold">∙</span> HNO<span class="Sub">3</span>, and the structural formula is as follows:</p>
<div class="Figure">
<a name="id416"></a><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=821073f7-33f6-464d-baed-f66d97987d6d&amp;name=ertaczo-01.jpg">
</div>
<p>Sertaconazole nitrate is a white or almost white powder. It is practically insoluble in water, soluble in methanol, sparingly soluble in alcohol and in methylene chloride. Each gram of ERTACZO cream, 2%, contains 17.5 mg of sertaconazole (as sertaconazole nitrate, 20 mg) in a white cream base of ethylene glycol, glyceryl isostearate, glycolized saturated glycerides, light mineral oil, methylparaben, polyethylene glycol palmitostearate, polyoxyethylened saturated glycerides, sorbic acid and purified water.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-9"></a><p></p>
<h1>12CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-9.1"></a><p></p>
<h2>12.1Mechanism of Action</h2>
<p class="First">ERTACZO cream is an azole antifungal [see <span class="Italics"><a href="#S12.4">Clinical Pharmacology (12.4)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-9.2"></a><p></p>
<h2>12.3Pharmacokinetics </h2>
<p class="First">In a multiple dose pharmacokinetic trial that included 5 male subjects with interdigital <span class="product-label-link" type="condition" conceptid="133141" conceptname="Tinea pedis">tinea pedis</span> (range of diseased area, 42 - 140 cm<span class="Sup">2</span>; mean, 93 cm<span class="Sup">2</span>), ERTACZO cream, 2%, was topically applied every 12 hours for a total of 13 doses to the diseased skin (0.5 grams sertaconazole nitrate per 100 cm<span class="Sup">2</span>). Sertaconazole concentrations in plasma measured by serial blood sampling for 72 hours after the thirteenth dose were below the limit of quantitation (2.5 ng/mL) of the analytical method used.</p>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="S12.4"></a><a name="section-9.3"></a><p></p>
<h2>12.4Microbiology</h2>
<p class="First"><span class="Bold"><span class="Underline">Mechanism of Action</span></span>:<br> Sertaconazole, an azole antifungal agent, inhibits fungal cytochrome P-450-mediated 14 alpha-lanosterol demethylase enzyme. This enzyme functions to convert lanosterol to ergosterol. Ergosterol is a key component of fungal cell membranes and lack of this component leads to fungal cell injury by leakage of key constituents in the cytoplasm from the cell.</p>
<p><span class="Bold"><span class="Underline">Activity <span class="Italics">In Vitro</span> and in Clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span></span>: <br>Sertaconazole nitrate has been shown to be active against isolates of the following microorganisms in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> [see <span class="Italics"><a href="#S1">Indications and Usage (1)</a></span>].</p>
<dl>
<dt> </dt>
<dd><span class="Italics">Trichophyton rubrum</span></dd>
<dt> </dt>
<dd><span class="Italics">Trichophyton mentagrophytes</span></dd>
<dt> </dt>
<dd><span class="Italics">Epidermophyton floccosum</span></dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-10"></a><p></p>
<h1>13NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-10.1"></a><p></p>
<h2>13.1Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">In a rat dermal carcinogenicity study, topical administration of sertaconazole nitrate cream for up to 102 weeks did not increase the number of neoplastic lesions compared to control animals, at sertaconazole nitrate doses of up to 800 mg/kg/day (approximately 200 times the maximum recommended human dose based on a body surface area comparison).</p>
<p>No clastogenic potential was observed in a mouse micronucleus test. Sertaconazole nitrate was considered nonclastogenic in the <span class="Italics">in vivo</span> mouse sister chromatid exchange assay. There was no evidence that sertaconazole nitrate induced unscheduled DNA synthesis in primary rat hepatocyte cultures.</p>
<p>At oral doses up to 60 mg/kg/day (16 times the maximum recommended human dose based on a body surface area comparison), sertaconazole nitrate exhibited no toxicity or adverse effects on reproductive performance or fertility in male or female rats.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-11"></a><p></p>
<h1>14CLINICAL STUDIES</h1>
<p class="First">In two randomized, double-blind, clinical trials, subjects 12 years and older with interdigital <span class="product-label-link" type="condition" conceptid="133141" conceptname="Tinea pedis">tinea pedis</span> applied either ERTACZO cream, 2%, or vehicle, twice daily for four weeks. Subjects with moccasin-type (plantar) <span class="product-label-link" type="condition" conceptid="133141" conceptname="Tinea pedis">tinea pedis</span> and/or <span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">onychomycosis</span> were excluded from the trial. Two weeks after completion of therapy (six weeks after beginning therapy), subjects were evaluated for signs and symptoms related to interdigital <span class="product-label-link" type="condition" conceptid="133141" conceptname="Tinea pedis">tinea pedis</span>.</p>
<p>Treatment outcomes are summarized in the table below.</p>
<a name="_RefID0EDPAC"></a><table width="100%">
<caption><span>Treatment Outcomes as Percent (%) of Total Subjects</span></caption>
<col width="39%">
<col width="16%">
<col width="15%">
<col width="16%">
<col width="15%">
<thead>
<tr class="First">
<th class="Botrule Lrule Toprule" align="left" valign="top"></th>
<th class="Botrule Lrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">Trial 1</span></th>
<th class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">Trial 2</span></th>
</tr>
<tr class="Last">
<th class="Botrule Lrule" align="left" valign="top"></th>
<th class="Botrule Lrule" align="center" valign="top"><span class="Bold">Sertaconazole</span></th>
<th class="Botrule Lrule" align="center" valign="top"><span class="Bold">Vehicle</span></th>
<th class="Botrule Lrule" align="center" valign="top"><span class="Bold">Sertaconazole</span></th>
<th class="Botrule Lrule Rrule" align="center" valign="top"><span class="Bold">Vehicle</span></th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd><span class="Bold">Complete Cure – Subjects who had complete clearing of signs and symptoms and Mycological Cure.</span></dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd><span class="Bold">Effective Treatment – Subjects who had minimal residual signs and symptoms of interdigital <span class="product-label-link" type="condition" conceptid="133141" conceptname="Tinea pedis">tinea pedis</span> and Mycological Cure.</span></dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd><span class="Bold">Mycological Cure – Subjects who had both negative microscopic KOH preparation and negative fungal culture.</span></dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Toprule"><p class="First"><span class="Bold">Complete Cure</span><a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a> (Primary Efficacy Variable)</p></td>
<td class="Botrule Lrule Toprule"><p class="First">13/99 (13.1%)</p></td>
<td class="Botrule Lrule Toprule"><p class="First">3/92 (3.3%)</p></td>
<td class="Botrule Lrule Toprule"><p class="First">28/103 (27.2%)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">5/103 (4.9%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="Bold">Effective Treatment</span><a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a></p></td>
<td class="Botrule Lrule"><p class="First">32/99 (32.3%)</p></td>
<td class="Botrule Lrule"><p class="First">11/92 (12.0%)</p></td>
<td class="Botrule Lrule"><p class="First">52/103 (50.5%)</p></td>
<td class="Botrule Lrule Rrule"><p class="First">16/103 (15.5%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First"><span class="Bold">Mycological Cure</span><a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a></p></td>
<td class="Botrule Lrule"><p class="First">49/99 (49.5%)</p></td>
<td class="Botrule Lrule"><p class="First">18/92 (19.6%)</p></td>
<td class="Botrule Lrule"><p class="First">71/103 (68.9%)</p></td>
<td class="Botrule Lrule Rrule"><p class="First">20/103 (19.4%)</p></td>
</tr>
</tbody>
</table>
<p>In clinical trials, complete cure in sertaconazole treated subjects was achieved in 32 of 160 (20%) subjects with <span class="Italics">Trichophyton rubrum</span>, in 7 of 28 (25%) subjects with <span class="Italics">Trichophyton mentagrophytes</span> and in 1 of 13 (15%) subjects with <span class="Italics">Epidermophyton floccosum</span>.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-12"></a><p></p>
<h1>16HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">ERTACZO cream, 2%, is white in color and supplied in tubes in the following size:</p>
<table width="60%">
<col width="22%">
<col width="47%">
<tbody class="Headless"><tr class="First Last">
<td class="Botrule Toprule"><p class="First">60-gram tube</p></td>
<td class="Botrule Toprule"><p class="First">NDC 0187-5115-60</p></td>
</tr></tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="ID_06047361-02de-422d-8232-5775a14dbdcc"></a><a name="section-12.1"></a><p></p>
<p class="First">Store at 20°C-25°C (68°F-77°F); excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled Room Temperature].</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-13"></a><p></p>
<h1>17PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Italics">See <a href="#_Ref">FDA-approved Patient Labeling (Patient Information)</a></span></p>
<p>The patient should be instructed to:</p>
<dl>
<dt>•</dt>
<dd> Use ERTACZO cream, 2%, as directed by the physician. The hands should be washed after applying the medication to the affected area(s). Avoid contact with the eyes, mouth, vagina and other mucous membranes. ERTACZO cream, 2%, is for external use only.</dd>
<dt>•</dt>
<dd> Dry the affected area(s) thoroughly before application, if you wish to use ERTACZO cream, 2%, after bathing.</dd>
<dt>•</dt>
<dd> Use the medication for the full treatment time recommended by the physician, even though symptoms may have improved.</dd>
<dt>•</dt>
<dd> Inform the physician if the area of application shows signs of increased irritation, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, burning, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blistering</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> or oozing.</dd>
<dt>•</dt>
<dd> Avoid the use of occlusive dressings unless otherwise directed by the physician.</dd>
<dt>•</dt>
<dd> Do not use this medication for any disorder other than that for which it was prescribed.</dd>
</dl>
<p>9378100</p>
<p>140248</p>
<p>Rev. 01/14</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="pi"></a><a name="section-14"></a><p></p>
<p class="First"><span class="Bold">PATIENT INFORMATION </span></p>
<p><span class="Bold">ERTACZO (er-tack-zo)</span><br><span class="Bold">(sertaconazole nitrate) cream, 2%</span></p>
<table width="100%">
<col width="100%">
<tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">Important information: ERTACZO cream is for use on skin only. Do not use ERTACZO cream in your eyes, mouth, or vagina.</span></p></td></tr></tbody>
</table>
<p><span class="Bold">What is ERTACZO cream?</span></p>
<p>ERTACZO cream is a prescription medicine used on the skin (topical) to treat athlete's foot that is between the toes (interdigital <span class="product-label-link" type="condition" conceptid="133141" conceptname="Tinea pedis">tinea pedis</span>) in people 12 years of age and older with normal immune systems.</p>
<p>It is not known if ERTACZO cream is safe and effective in children under 12 years of age.</p>
<p><span class="Bold">What should I tell my healthcare provider before using ERTACZO cream?</span></p>
<p>Before using ERTACZO cream, tell your healthcare provider about all of your medical conditions, including if you:</p>
<dl>
<dt>•</dt>
<dd>have any allergies</dd>
<dt>•</dt>
<dd>are pregnant or plan to become pregnant. It is not known if ERTACZO cream will harm your unborn baby.</dd>
<dt>•</dt>
<dd>are breastfeeding or plan to breastfeed. It is not known if ERTACZO cream passes into your breast milk.</dd>
</dl>
<p><span class="Bold">Tell your healthcare provider about all of the medicines you take,</span> including prescription and over-the-counter medicines, vitamins, and herbal supplements.</p>
<p><span class="Bold">How should I use ERTACZO cream?</span></p>
<dl>
<dt>•</dt>
<dd>Use ERTACZO cream exactly as your healthcare provider tells you to use it.</dd>
<dt>•</dt>
<dd>Use ERTACZO cream for the full treatment time, even if your symptoms improve.</dd>
<dt>•</dt>
<dd>If you take a bath or shower, dry the affected skin areas well before you apply ERTACZO cream.</dd>
<dt>•</dt>
<dd>Apply ERTACZO cream 2 times a day for 4 weeks to the affected skin areas between your toes and to the healthy skin around the affected areas.</dd>
<dt>•</dt>
<dd>Wash your hands after you apply ERTACZO cream</dd>
<dt>•</dt>
<dd>Do not cover the treated skin areas with bandages unless your healthcare provider tells you to.</dd>
</dl>
<p><span class="Bold">What are the possible side effects of ERTACZO cream?</span></p>
<p><span class="Bold">The most common side effects of ERTACZO cream include:</span> <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>, burning, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blistering</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, drainage and <span class="product-label-link" type="condition" conceptid="4115411" conceptname="Pain of skin">skin tenderness</span> at the treated skin areas. Tell your healthcare provider if you have any of these <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>.</p>
<p>These are not all the possible side effects of ERTACZO cream. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store ERTACZO cream?</span></p>
<dl>
<dt>•</dt>
<dd>Store ERTACZO cream at room temperature, between 68°F to 77°F (20°C to 25°C).</dd>
<dt>•</dt>
<dd>Keep ERTACZO cream and all medicines out of the reach of children.</dd>
</dl>
<p><span class="Bold">General information about the safe and effective use of ERTACZO cream</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. You can ask your healthcare provider or pharmacist for information about ERTACZO cream that is written for health professionals. Do not use ERTACZO cream for a condition for which it was not prescribed. Do not give ERTACZO cream to other people, even if they have the same symptoms you have. It may harm them.</p>
<p><span class="Bold">What are the ingredients in ERTACZO cream?</span></p>
<p>Active ingredient: sertaconazole nitrate</p>
<p>Inactive ingredients: ethylene glycol, glyceryl isostearate, glycolized saturated glycerides, light mineral oil, methylparaben, polyethylene glycol palmitostearate, polyoxyethylened saturated glycerides, sorbic acid and purified water</p>
<p>Distributed by: Valeant Pharmaceuticals North America LLC, Bridgewater, NJ 08807</p>
<p>Manufactured by: DPT Laboratories, Ltd., San Antonio, TX  78215</p>
<p>Product of Spain</p>
<p>For more information call 1-800-321-4567.</p>
<p>This Patient Information has been approved by the U.S. Food and Drug Administration.</p>
<p>9378100</p>
<p>140248</p>
<p>Rev. 01/14</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_e6a345a2-b640-4a6c-887c-d7ebd8a1d6e6"></a><a name="section-15"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 60 g Tube</span></p>
<p><span class="Bold">NDC</span> 0187-5115-60</p>
<p><span class="Bold"><span class="Italics">ERTACZO<span class="Sup">®</span></span></span><br><span class="Italics">(sertaconazole nitrate) cream, 2%</span></p>
<p>For Topical Use Only – Not for Oral, Ophthalmic, or Intravaginal Use</p>
<div class="Figure">
<a name="id691"></a><img alt="PRINCIPAL DISPLAY PANEL - 60 g Tube" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=821073f7-33f6-464d-baed-f66d97987d6d&amp;name=ertaczo-02.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ERTACZO 		
					</strong><br><span class="contentTableReg">sertaconazole nitrate cream</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0187-5115</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Sertaconazole Nitrate</strong> (Sertaconazole) </td>
<td class="formItem">Sertaconazole Nitrate</td>
<td class="formItem">20 mg  in 1 g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Ethylene Glycol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Glyceryl Isostearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Light Mineral Oil</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Methylparaben</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sorbic Acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0187-5115-60</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">60 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0187-5115-02</td>
<td class="formItem">18  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">2 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021385</td>
<td class="formItem">12/10/2003</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Valeant Pharmaceuticals North America LLC
							(042230623)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">DPT Laboratories, Ltd.</td>
<td class="formItem"></td>
<td class="formItem">832224690</td>
<td class="formItem">MANUFACTURE(0187-5115)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 1/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>6bfa4c28-87d4-4acd-916f-7bc3bf31f1a7</div>
<div>Set id: 821073f7-33f6-464d-baed-f66d97987d6d</div>
<div>Version: 6</div>
<div>Effective Time: 20140125</div>
</div>
</div> <div class="DistributorName">Valeant Pharmaceuticals North America LLC</div></p>
</body></html>
